The company said that this is the first issuance from a series of patent applications covering its XmAb antibody Fc engineering technology, which is comprised of a suite of thousands of selectively engineered Fc domains. Xencor added that its engineered Fc domains have been shown to improve antibody potency against tumor cells by more than 100-fold, significantly extend in vivo half-life and have been partnered with several large biotechnology and pharmaceutical companies to enhance specific clinical candidates.
Bassil Dahiyat, president and CEO of Xencor, said: “This is an important milestone for the continued implementation of our Fc technology, which will soon enter Phase I clinical testing in our lead clinical candidate, XmAb2513. Our team is actively pursuing a series of additional patents that will comprehensively cover the broad range of applications we have created with our Fc technology.”